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Background
Brazilian guidelines stipulate that HIV+ pregnant women
initiating HAART for PMTCT, who do not otherwise need
ARV for their own health, discontinue antiretrovirals after
delivery. However, it is unknown how frequent drug
resistance is with this strategy.
Objectives
to evaluate HIV-1 primary resistance at baseline visit, the
impact of antiretroviral discontinuation, following deliv-
ery for the emergence of genotypic resistance, HIV-1 sub-
type, HIV-1 recent Infection using the Calypte BED
Incidence EIA, and the rates of HIV-1 vertical transmission
in this population of HIV-1 pregnant women.
Methods
Since January 2005, an HIV+ pregnant women cohort has
been established at Hospital Geral de Nova Iguaçu.
HAART for PMTCT was used according to the Brazilian
Guidelines. Clinical/lab evaluations (CD4, HIV-RNA and
genotyping were performed at baseline, 6–8 weeks after
HAART, delivery and postpartum [15 days, 1 month and
6 months]).
Results
139 women/babies have been enrolled and followed.
Median age is 25.3 years; 69.8% women are non-white,
median gestational age at prenatal care initiation is 24
weeks. Median CD4 cell count at baseline is 518 cells/
mm3 and HIV-1 VL 7.800 copies/mL. A NNRTI and PI
based regimen was prescribed for 22.3% and 77.7% of the
women, respectively. The median time on ART was 84
days; 76% had HIV-1 RNA <400 copies/ml at delivery.
The prevalence of HIV primary drug resistant was 11.3%
at baseline visit, and 13.8% of the women developed new
mutations after ART interruption at delivery. HIV-1 recent
infection was detected in 13.9% pregnant women at base-
line visit. In the multivariate analysis, HIV-1 primary
resistance was independently associated with the develop-
ment of new resistance mutations at delivery/post-par-
tum. Pregnant women with detectable HIV-1 RNA at
delivery had a RR of detection of mutations at delivery/
post-partum 3.5 times the one for women with undetect-
able HIV-1 RNA at delivery. The length of time of HAART
use was independently associated with the incidence of
resistance after ART initiation for PMTCT.
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High Prevalence of HIV-1 primary resistance at baseline
visit; 13.8% of the women developed new mutations after
ART interruption after delivery. HIV-1 recent infection was
detected in 13.9% pregnant women at baseline visit. HIV
subtype B was the most prevalent. There was no HIV-1 ver-
tical transmission.Page 2 of 2
(page number not for citation purposes)
